Maintain vision and improve ocular health Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com Pharmaceuticals, Ophthalmology, and Research and Development

81 similar entities Type: SMB Activities: healthtech manufacturing Technologies: Synthetic Biology

VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for YAG laser capsulotomy after surgery, our device has the potential to revolutionise cataract surgery in both the human and veterinary markets.

23 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating value in eye health for our patients worldwide VISUfarma is a pan-European ophthalmic pharmaceutical company with a clear mission: to bring quality products and global therapeutic innovation to European eye health. We are an ambitious and fast growing ophthalmology company, commercializing a broad portfolio of pharmaceutical products and medical devices across Europe. (www.VISUfarma.com). The company was formed in 2016 and is the result of the successful combination of the Italian company Visufarma SpA and the commercial activities of the international Nicox SA, headquartered in France. The combination created VISUfarma. We offer a complete portfolio of products in the areas …

Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Visionary Care Since 1935 always committed to improve patients’ quality of vision. SIFI is expanding into international market providing innovative solutions for ocular diseases. Eye Care, Pharmaceutical/Nutraceuticals/Medical Devices, Surgical & Diagnostic Medical Devices., Ophthalmology , Science, Researchers , Research, Vision, Eyes, Surgical, Medical technology, Health, Medicine , Eye health , and Biotech

62 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A WuXi Advanced Therapies company, based in Oxford, UK. OXGENE, a WuXi Advanced Therapies (WuXi ATU) company, based in Oxford, UK, provides cell and gene therapy pioneers around the world with the technologies, automation platforms and service solutions they need to come first in the race to deliver ground-breaking therapeutics. OXGENETM is headquartered in Oxford, UK. For additional information, please visit our website. PRODUCTS: Largest collection of standardised plasmids on the market and SERVICES: DNA Services, Protein Production Services, Virus Services, Cell Line Development Services.

52 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology